Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 7 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $14.7B (to Q2 2026). Free Cash Flow: $1.95B, trailing twelve months to Q2 2026. Op Margin: −0.64%, trailing twelve months to Q2 2026. EPS: −$0.36, trailing twelve months to Q2 2026.

VTRSViatris

HealthcareUSD

$16.86

$9.0352 weeks$17.87

VTRS as reported

Viatris reported $14.7B of revenue over the trailing twelve months, +4.4% on the year before. 7 reported series are charted on this page, each one as filed.

$14.7B

Revenue, trailing twelve months · to Q2 2026 · +4.4% against the twelve months before

Free Cash Flow: $1.95B
Free Cash Flow · +12% year on year · trailing twelve months to Q2 2026
Op Margin: −0.64%
Op Margin · trailing twelve months to Q2 2026
EPS: −$0.36
EPS · −88% year on year · trailing twelve months to Q2 2026

Every series Ryufin has for VTRS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$14.7B	+4.4%	Q2 2026
EPS	−$0.36	−88%	Q2 2026
Gross Margin	35%	n/a	Q2 2026
Op Margin	−0.64%	n/a	Q2 2026
ROIC	−3.7%	n/a	Q2 2026
Free Cash Flow	$1.95B	+12%	Q2 2026
P/E	52.9	n/a	Q4 2023 · 10 quarters behind